Insulin resistance markers in children

Francisca Eyzaguirre1, Verónica Mericq

  • 1Institute of Maternal and Child Research, University of Chile, Santiago, Chile.

Hormone Research
|January 9, 2009
PubMed

Insights

Childhood obesity is rising, increasing insulin resistance (IR) risk. This review explores biochemical markers for diagnosing IR in children, addressing a gap in pediatric reference data.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Childhood obesity prevalence is increasing globally.
  • Obesity is a major risk factor for insulin resistance (IR) and associated comorbidities.
  • IR in children can lead to serious health issues like diabetes and cardiovascular disease.

Purpose of the Study:

  • To review current biochemical markers for evaluating insulin sensitivity in children.
  • To discuss the utility of various hormones and inflammatory markers in diagnosing pediatric IR.
  • To highlight the lack of established reference data for these markers in pediatric populations.

Main Methods:

  • Literature review of biochemical markers for insulin resistance.
  • Analysis of established indices for insulin sensitivity assessment.
  • Examination of hormonal and inflammatory markers relevant to IR.
  • Discussion of diagnostic approaches for pediatric IR.

Main Results:

  • Several biochemical markers, including homeostatic model assessment and quantitative insulin sensitivity check index, can assess insulin sensitivity.
  • Hormones like leptin, adiponectin, and resistin, along with inflammatory markers such as C-reactive protein and IL-6, are relevant.
  • A significant gap exists in validated reference data for these markers in children.

Conclusions:

  • Accurate diagnosis of IR in children requires reliable biochemical markers.
  • Further research is needed to establish pediatric-specific reference ranges for IR markers.
  • Standardized diagnostic criteria are essential for managing pediatric IR effectively.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...